MRNA:OTCQB-Marina Biotech Inc (USD)

COMMON STOCK | Biotechnology | OTCQB - U.S. Registered

Last Closing

USD 164.01

Change

+0.68 (+0.42)%

Market Cap

USD 0.02B

Volume

7.10M

Analyst Target

USD 89.73
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Marina Biotech Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 124.65B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 110.51B
BNTX BioNTech SE

N/A

USD 24.18B
ARGX argenx NV ADR

N/A

USD 23.04B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 20.29B
GMAB Genmab AS

N/A

USD 18.17B
BGNE BeiGene Ltd

N/A

USD 17.74B
RPRX Royalty Pharma Plc

N/A

USD 16.18B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.32B
INCY Incyte Corporation

N/A

USD 13.30B

ETFs Containing MRNA

MRN3:LSE Leverage Shares 3x Long M.. 300.13 % 0.00 %

N/A

USD 0.45M
CURE:XETRA VanEck Genomics and Healt.. 9.78 % 0.00 %

N/A

USD 6.98M
CURG:LSE VanEck Genomics and Healt.. 9.68 % 0.00 %

N/A

USD 6.90M
XGEN:XETRA Xtrackers MSCI Genomic He.. 7.82 % 0.00 %

N/A

USD 3.55M
XGES:LSE Xtrackers MSCI Genomic He.. 7.82 % 0.00 %

N/A

USD 3.55M
MSGR 6.26 % 0.00 %

N/A

N/A
2B70:F iShares NASDAQ US Biotech.. 5.63 % 0.00 %

N/A

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 5.63 % 0.00 %

N/A

USD 0.52B
BTEC:SW iShares Nasdaq US Biotech.. 5.63 % 0.00 %

N/A

USD 0.51B
GN0M:XETRA Global X Genomics & Biote.. 5.25 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 5.25 % 0.00 %

N/A

USD 6.38M
XDNA:CA iShares Genomics Immunolo.. 5.19 % 0.00 %

N/A

CAD 5.15M
GNOG:LSE Global X Genomics & Biote.. 4.96 % 0.00 %

N/A

USD 6.81M
HVAX:CA 4.95 % 0.00 %

N/A

N/A
BTEC Principal Healthcare Inno.. 4.57 % 0.42 %

N/A

USD 0.03B
XNNV:XETRA Xtrackers MSCI Innovation.. 3.95 % 0.00 %

N/A

USD 8.01M
XNNS:LSE Xtrackers MSCI Innovation.. 3.95 % 0.00 %

N/A

USD 8.01M
XNNV:LSE Xtrackers MSCI Innovation.. 3.95 % 0.00 %

N/A

USD 8.01M
LSEQ Harbor Long-Short Equity .. 3.72 % 0.00 %

N/A

USD 0.01B
CDNA:CA CI Bio-Revolution ETF 3.71 % 0.00 %

N/A

CAD 5.88M
ARCG:LSE ARK Genomic Revolution UC.. 3.64 % 0.00 %

N/A

USD 2.44M
DOCG:LSE L&G Healthcare Breakthrou.. 2.80 % 0.00 %

N/A

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 2.80 % 0.00 %

N/A

USD 0.07B
XMLH:F Legal & General Ucits Etf.. 2.65 % 0.00 %

N/A

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 2.65 % 0.00 %

N/A

USD 0.07B
QQXT First Trust NASDAQ-100 Ex.. 2.47 % 0.60 %

N/A

USD 0.13B
RSPH Invesco S&P 500® Equal.. 2.26 % 0.00 %

N/A

USD 1.02B
XBI SPDR® S&P Biotech ETF 1.55 % 0.35 %

N/A

USD 7.07B
QQEW First Trust NASDAQ-100 Eq.. 1.47 % 0.60 %

N/A

USD 2.06B
TAEQ 1.46 % 0.00 %

N/A

N/A
WEBA:XETRA Amundi US Tech 100 Equal .. 1.41 % 0.00 %

N/A

USD 0.58B
QQQE Direxion NASDAQ-100 Equal.. 1.39 % 0.35 %

N/A

USD 1.16B
CURE:AU ETFS S&P Biotech ETF 1.22 % 0.00 %

N/A

USD 0.04B
JKI iShares Morningstar Mid-C.. 1.01 % 0.30 %

N/A

USD 0.60B
LABU Direxion Daily S&P Biotec.. 0.90 % 1.14 %

N/A

USD 1.10B
RSPE Invesco Exchange-Traded F.. 0.80 % 0.00 %

N/A

USD 8.86M
WELE:XETRA Amundi S&P 500 Equal Weig.. 0.73 % 0.00 %

N/A

USD 0.83B
XEXP:CA iShares Exponential Techn.. 0.68 % 0.00 %

N/A

CAD 0.02B
XZEW:XETRA Xtrackers S&P 500 Equal W.. 0.51 % 0.00 %

N/A

USD 0.60B
DFVE Doubleline Fortune 500 Eq.. 0.31 % 0.00 %

N/A

USD 0.01B
EWSP:LSE iShares S&P 500 Equal Wei.. 0.30 % 0.00 %

N/A

USD 1.31B
XDEW:F Xtrackers (IE) Public Lim.. 0.30 % 0.00 %

N/A

USD 5.75B
XEWG:LSE Xtrackers S&P 500 Equal W.. 0.30 % 0.00 %

N/A

USD 0.07B
XDED:XETRA Xtrackers S&P 500 Equal W.. 0.30 % 0.00 %

N/A

USD 6.28B
XDEW:SW Xtrackers S&P 500 Equal W.. 0.30 % 0.00 %

N/A

USD 5.76B
SPEX:LSE Invesco S&P 500 Equal Wei.. 0.29 % 0.00 %

N/A

USD 0.21B
ISPE:LSE iShares S&P 500 Equal Wei.. 0.29 % 0.00 %

N/A

USD 0.42B
SPED:LSE Invesco S&P 500 Equal Wei.. 0.28 % 0.00 %

N/A

USD 0.07B
SPEQ:LSE Invesco S&P 500 Equal Wei.. 0.28 % 0.00 %

N/A

USD 0.21B
SPES:LSE Invesco S&P 500 Equal Wei.. 0.28 % 0.00 %

N/A

USD 0.07B
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

N/A

USD 1.31B
ARKG 0.00 % 0.75 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

N/A

USD 0.44B
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

N/A

USD 0.02B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD 0.09B
ETHO Etho Climate Leadership U.. 0.00 % 0.45 %

N/A

USD 0.18B
FLAG 0.00 % 1.52 %

N/A

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 7.34B
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

N/A

CAD 0.05B
LS:CA Middlefield Healthcare & .. 0.00 % 2.21 %

N/A

CAD 0.16B
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

N/A

USD 0.09B
HWF:CA 0.00 % 0.00 %

N/A

N/A
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

N/A

USD 0.06B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.47B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.47B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.04B
RSP Invesco S&P 500® Equal W.. 0.00 % 0.20 %

N/A

USD 55.39B
RYH 0.00 % 0.40 %

N/A

N/A
XT iShares Exponential Techn.. 0.00 % 0.47 %

N/A

USD 3.36B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

USD 1.06B
XDEW:LSE Xtrackers S&P 500 Equal W.. 0.00 % 0.00 %

N/A

USD 5.73B
XDWE:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

N/A

USD 5.78B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
XMLH:XETRA L&G Healthcare Breakthrou.. 0.00 % 0.00 %

N/A

USD 0.07B
GERM ETFMG Treatments Testing .. 0.00 % 0.00 %

N/A

USD 0.01B
IMCV iShares Morningstar Mid-C.. 0.00 % 0.00 %

N/A

USD 0.60B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.03B
MRNS:LSE Leverage Shares -3x Short.. -299.96 % 0.00 %

N/A

USD 0.08M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTCQB - U.S. Registered)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 64.88% 87% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.88% 87% B+ 93% A
Trailing 12 Months  
Capital Gain 29.68% 78% C+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.68% 78% C+ 79% B-
Trailing 5 Years  
Capital Gain 651.31% 97% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 651.31% 97% N/A 97% N/A
Average Annual (5 Year Horizon)  
Capital Gain 136.53% 94% A 96% N/A
Dividend Return 136.53% 94% A 96% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 222.02% 12% F 7% C-
Risk Adjusted Return 61.49% 97% N/A 86% B+
Market Capitalization 0.02B 100% F 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector